Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ADMA: its role in vascular disease.

John P Cooke1

  • 1Division of Cardiovascular Medicine, Stanford University School of Medicine, Falk Cardiovascular Research Center, CA 94305-5406, USA. john.cooke@stanford.edu

Vascular Medicine (London, England)
|February 1, 2006
PubMed
Summary

Asymmetric dimethylarginine (ADMA) impairs nitric oxide (NO) pathways, increasing vascular disease risk. Lowering ADMA levels may offer new therapeutic strategies for cardiovascular conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exercise Capacity, Endothelial Function, Muscle Mass, and Strength in Pediatric Patients With Fontan Circulation.

CJC pediatric and congenital heart disease·2026
Same author

Human BMP4 mRNA Encapsulated in Lipid Nanoparticle for Bone and Articular Cartilage Repair in Aged Mice.

Journal of functional biomaterials·2026
Same author

Investigational New Drug-enabling studies in a human vessel-chip: Are we there yet?

Bioengineering & translational medicine·2026
Same author

Telomerase is induced during wound healing across species.

Skin health and disease·2026
Same author

LATS1/2-CD38 Metabolic Rewiring Links Senescence to Intraplaque Thrombosis.

Circulation research·2026
Same author

A Long-lived Avatar for Modeling Age-Related Vascular Disease.

bioRxiv : the preprint server for biology·2026

Area of Science:

  • Cardiovascular Science
  • Endothelial Biology
  • Pharmacology

Background:

  • Endothelium-derived nitric oxide (NO) is a key vasodilator and anti-atherogenic agent.
  • Impaired NO synthesis or activity elevates vascular disease risk.
  • Asymmetric dimethylarginine (ADMA) inhibits NO synthase, and elevated plasma ADMA is linked to vascular disease.

Purpose of the Study:

  • To investigate the role of ADMA in endothelial dysfunction and vascular disease.
  • To explore ADMA as a potential mediator of vascular risk factors.
  • To identify therapeutic targets related to ADMA regulation.

Main Methods:

  • Review of preclinical and clinical studies on ADMA and endothelial function.
  • Analysis of ADMA levels in patients with vascular disease and risk factors.
  • Examination of the effects of cardiovascular drugs on plasma ADMA levels.

Main Results:

  • Elevated plasma ADMA levels are observed in patients with vascular disease and risk factors.
  • ADMA may mediate the negative impact of risk factors on endothelial vasodilator function.
  • Certain cardiovascular drugs effectively reduce plasma ADMA levels.

Conclusions:

  • ADMA is implicated in mediating endothelial dysfunction and contributes to hypertension and vascular disease.
  • Plasma ADMA may serve as a common pathway for endothelial dysfunction induced by vascular risk factors.
  • Understanding ADMA regulation could unlock novel therapeutic approaches for cardiovascular diseases.

Related Experiment Videos